- Home
- DEVS vs BIAF Comparison
DEVS vs BIAF Comparison
Compare DEVS & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DEVS
- BIAF
- Stock Information
- Founded
- DEVS N/A
- BIAF 2014
- Country
- DEVS Canada
- BIAF United States
- Employees
- DEVS N/A
- BIAF N/A
- Industry
- DEVS
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- DEVS
- BIAF Health Care
- Exchange
- DEVS NYSE
- BIAF Nasdaq
- Market Cap
- DEVS 11.9M
- BIAF 12.2M
- IPO Year
- DEVS N/A
- BIAF 2022
- Fundamental
- Price
- DEVS $0.43
- BIAF $0.36
- Analyst Decision
- DEVS
- BIAF Hold
- Analyst Count
- DEVS 0
- BIAF 1
- Target Price
- DEVS N/A
- BIAF N/A
- AVG Volume (30 Days)
- DEVS 722.8K
- BIAF 12.1M
- Earning Date
- DEVS 07-29-2025
- BIAF 08-13-2025
- Dividend Yield
- DEVS N/A
- BIAF N/A
- EPS Growth
- DEVS N/A
- BIAF N/A
- EPS
- DEVS N/A
- BIAF N/A
- Revenue
- DEVS $10,164.00
- BIAF $8,809,228.00
- Revenue This Year
- DEVS N/A
- BIAF N/A
- Revenue Next Year
- DEVS N/A
- BIAF $20.00
- P/E Ratio
- DEVS N/A
- BIAF N/A
- Revenue Growth
- DEVS N/A
- BIAF 78.40
- 52 Week Low
- DEVS $0.18
- BIAF $0.16
- 52 Week High
- DEVS $3.00
- BIAF $2.99
- Technical
- Relative Strength Index (RSI)
- DEVS N/A
- BIAF 59.13
- Support Level
- DEVS N/A
- BIAF $0.27
- Resistance Level
- DEVS N/A
- BIAF $0.36
- Average True Range (ATR)
- DEVS 0.00
- BIAF 0.05
- MACD
- DEVS 0.00
- BIAF 0.01
- Stochastic Oscillator
- DEVS 0.00
- BIAF 97.52
About DEVS DEVVSTREAM CORP
DevvStream Corp is a technology-based ESG company that advances the development and monetization of environmental assets, with an initial focus on carbon markets. It works with governments and corporations to achieve its sustainability goals through the implementation of curated green technology projects that generate renewable energy, improve energy efficiencies, eliminate or reduce emissions, and sequester carbon directly from the air.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.